Stryker wins FDA nod for new total ankle system
Stryker has received FDA 510(k) clearance for its Incompass total ankle system, designed for patients with ankle joints damaged by severe arthritis. The system integrates technologies from its Inbone and Infinity systems, incorporating Adaptis boney ingrowth technology and redesigned instrumentation for enhanced flexibility and efficiency. Stryker utilized extensive data from CT scans and clinical cases to develop this personalized care solution.
AHA, ACC issue guidelines for pulmonary embolism that affect Boston Scientific, Stryker
New guidelines from the American Heart Association (AHA) and American College of Cardiology (ACC) for pulmonary embolism (PE) could significantly benefit Boston Scientific and Stryker, particularly their mechanical thrombectomy (MT) systems. The updated guidelines, the first since 2011, introduce a new classification scheme for PE severity and assign a higher level of evidence for MT use, maintaining its recommendation for massive and submassive PE. Analysts believe this update, which includes detailed categories for risk assessment and therapeutic decision-making, could boost both companies' market position.
William Blair initiates Stryker stock coverage citing diversified growth By Investing.com
William Blair initiated coverage on Stryker Corporation (NYSE:SYK) with an Outperform rating, forecasting faster sales and EPS growth due to its diversified product portfolio, including recent acquisitions in new markets and increased AI/data offerings. The company, a prominent player in the Healthcare Equipment & Supplies industry, has expanded its reach beyond traditional segments and exhibits strong revenue growth and margin expansion goals, despite trading above its fair value according to InvestingPro analysis. Recent strong Q4 results and product launches like the Mako RPS further underscore its growth trajectory.
William Blair initiates Stryker stock coverage citing diversified growth
William Blair has initiated coverage on Stryker Corporation (NYSE:SYK) with an Outperform rating, citing the medical technology giant's diversified growth product portfolio, achieved primarily through strategic mergers and acquisitions. The firm anticipates Stryker will achieve faster sales and earnings per share growth compared to its peers over the next two years, driven by expansion into new markets and enhanced artificial intelligence offerings. Despite a recent 11% revenue growth, InvestingPro analysis indicates the stock is currently trading above its Fair Value.
Neurosurgery Market Is Going to Boom |Medtronic, Stryker Corporation, Zimmer Biomet, Johnson & Johnson
The global neurosurgery market is projected to grow from USD 4.10 billion in 2026 to USD 5.69 billion by 2033, exhibiting a CAGR of 4.8%. This growth is driven by increasing industry demand, expanding applications, and technological advancements. The report by Coherent Market Insights provides a comprehensive analysis of market size, revenue trends, key growth factors, competitive landscape, and strategic opportunities for stakeholders.
Robotic Surgical Systems Market Is Going to Boom | Intuitive
Coherent Market Insights has published a new research report on the Robotic Surgical Systems Market, forecasting substantial growth from 2026 to 2033. The report offers a deep dive into market trends, drivers, and competitive landscapes, featuring key players like Intuitive Surgical, Medtronic, and Johnson & Johnson. It provides comprehensive segmentation, regional analysis, and strategic insights for businesses in the healthcare sector.
J&J Explores $20 Billion-Plus Sale of Orthopedics Unit
Johnson & Johnson is reportedly exploring a sale of its orthopedics unit, DePuy Synthes, which could be valued at over $20 billion. The company is preparing documents for potential buyers, including large private equity firms and rival medical device players. This move comes after J&J announced plans in October to separate the slower-growing business, considering options like a spinoff or sale for greater value.
April 17th Options Now Available For Stryker (SYK)
New options for Stryker (SYK) with an April 17th expiration are now trading. Using their YieldBoost formula, Stock Options Channel identified a put contract at a $360.00 strike and a call contract at a $380.00 strike, offering attractive potential returns for investors considering buying or selling SYK shares. These contracts provide opportunities for a discounted purchase price or enhanced income through covered calls, with outlined probabilities of expiring worthless and annualized returns.
Boston Scientific’s $14.5B Penumbra Mega-Merger: A Strategic Reshaping of the Medtech Landscape
Boston Scientific (NYSE: BSX) is acquiring Penumbra, Inc. (NYSE: PEN) for $14.5 billion, a move that will reshape the medtech industry by positioning Boston Scientific as a dominant player in neurovascular and thrombectomy markets. This acquisition, structured as 73% cash and 27% stock, signals a strategic return to the neurovascular space for Boston Scientific and highlights a broader trend of consolidation and "Industrialization" within the medical technology sector. The deal is expected to create a duopoly with Stryker in the mechanical thrombectomy market, putting pressure on competitors like Medtronic.
Burling Wealth Partners LLC Boosts Holdings in Stryker Corporation $SYK
Burling Wealth Partners LLC increased its stake in Stryker Corporation (NYSE:SYK) by 34.6% in the third quarter, bringing their total holdings to 11,743 shares valued at over $4.3 million. Other institutional investors also adjusted their positions in Stryker, which recently reported strong quarterly earnings of $4.47 EPS and revenue of $7.17 billion, surpassing analyst expectations. The company also announced a quarterly dividend of $0.88 per share, while analysts currently hold a "Moderate Buy" rating with a consensus target price of $426.94.
Comgest Global Investors S.A.S. Has $36.58 Million Position in Stryker Corporation $SYK
Comgest Global Investors S.A.S. increased its stake in Stryker Corporation by 16.2% in the third quarter, bringing their total holdings to $36.58 million. This makes Stryker their 27th largest holding, accounting for about 0.6% of their portfolio. The article also details other institutional investor activity, an insider sale by Director Ronda E. Stryker, current analyst ratings, and the company's recent financial performance and dividend announcement.
King Luther Capital Management Corp Boosts Stock Holdings in Stryker Corporation $SYK
King Luther Capital Management Corp increased its holdings in Stryker Corporation (NYSE:SYK) by 3.2% in the third quarter, now owning 461,653 shares valued at over $170 million. Other institutional investors also adjusted their stakes, with hedge funds and institutional investors collectively owning 77.09% of the company's stock. Stryker recently reported strong quarterly earnings, surpassing analyst estimates, and announced a quarterly dividend of $0.88 per share.
Liquid Handling System Market Is Going to Boom | Thermo Fisher Scientific • Eppendorf AG • Sartorius AG • Gilson Inc
A new report by Coherent Market Insights projects significant growth for the Liquid Handling System Market between 2026 and 2033, driven by various factors including increased demand and technological advancements. The comprehensive analysis covers market size, trends, competitive landscape, regional insights, and future growth opportunities. Key players identified include Thermo Fisher Scientific, Eppendorf AG, Sartorius AG, and Gilson Inc.
Stryker Corporation $SYK Stake Trimmed by 626 Financial LLC
626 Financial LLC reduced its stake in Stryker Corporation by 3.9% in the third quarter, making it their largest holding at 12.5% of their portfolio, valued at $28.47 million. Insider selling also occurred, with Director Ronda E. Stryker selling 250,000 shares for $90.73 million and CFO Preston Wendell Wells selling 165 shares. Despite the trimmed institutional stake and insider sales, Stryker reported strong Q3 earnings, beating analyst estimates, and maintains a "Moderate Buy" consensus rating with a $426.94 price target.
$2.12 Pre Market 18 Feb 2026: MBOT Microbot Medical Inc NASDAQ – 91% upside
Microbot Medical Inc. (MBOT) is trading at $2.12 pre-market on February 18, 2026, with a market cap of $96.6 million and rising short-term momentum. The article provides an AI-driven view of the stock's risks and potential upside, highlighting strong liquidity but negative earnings. Meyka AI projects a 91.26% upside, with a yearly target of $4.06 USD, based on historical patterns, sector signals, and analyst consensus.
Medtronic plc Q3 FY2026 Earnings: Revenue Hits $9.0B With Highest Enterprise Growth in 10 Quarters
Medtronic plc reported stronger-than-expected Q3 FY2026 earnings, with non-GAAP EPS of $1.36 and revenue of $9.017 billion, marking the highest enterprise growth in 10 quarters. Despite beating analyst estimates for both revenue and EPS, Medtronic's shares fell approximately 3.2% as the company reiterated its full-year guidance rather than raising it. The company's Cardiovascular portfolio saw significant growth, particularly in Cardiac Ablation Solutions, although GAAP net income declined due to increased expenses.
Baxter Restructuring And Divestiture Plan Tests Turnaround And Valuation Case
Baxter International (NYSE:BAX) is initiating a significant restructuring, including separating its Kidney Care business and implementing a decentralized operating model, following a challenging financial year. Despite a 72.1% stock decline over five years, the company aims to improve profitability and efficiency, with management expecting flat to 1% GAAP sales growth in 2026. Investors face elevated execution risk during this turnaround, but analysts anticipate future earnings and revenue growth, and the stock is considered to be trading at a discount to its fair value.
W.G. Shaheen & Associates DBA Whitney & Co Has $9.64 Million Position in Stryker Corporation $SYK
W.G. Shaheen & Associates DBA Whitney & Co has reduced its stake in Stryker Corporation by 13.5%, now holding 26,086 shares valued at $9.64 million. Despite this reduction, several other institutional investors increased their positions in SYK. Meanwhile, a director of Stryker sold a significant number of shares, valued at over $90 million, though analysts maintain a "Moderate Buy" rating with an average target price of $426.94.
Skandinaviska Enskilda Banken AB publ Sells 3,223 Shares of Stryker Corporation $SYK
Skandinaviska Enskilda Banken AB publ has reduced its stake in Stryker Corporation (NYSE:SYK) by selling 3,223 shares, bringing its total ownership to 348,478 shares valued at approximately $128.82 million. This comes as Stryker reported strong Q3 earnings, beating analyst expectations with $4.47 EPS and $7.17 billion in revenue, leading to analysts raising price targets and maintaining a "Moderate Buy" consensus. The company also announced a quarterly dividend of $0.88, while key insiders, including Director Ronda E. Stryker, have recently sold significant shares.
Medtronic (MDT): The Sleeping Giant Awakes with Strong Q3 FY26 Momentum
Medtronic (MDT) has transitioned from a stable but slow-moving company to a high-growth contender, driven by its revitalized cardiovascular portfolio and a successful "Medtronic Mindset" culture shift, as evidenced by its strong Q3 FY26 results. The company posted impressive organic revenue growth of 5.8% and expanded operating margins, while its robust product pipeline, including Pulsed Field Ablation and the Hugo RAS system, positions it to reclaim market share in key medical technology segments. Despite competitive and regulatory challenges, Medtronic's diversified portfolio, strong leadership, and focus on innovation provide a solid foundation for continued growth and an attractive dividend for investors.
Crestwood Advisors Group LLC Decreases Stake in Stryker Corporation $SYK
Crestwood Advisors Group LLC reduced its stake in Stryker Corporation by 10.4% in the third quarter, selling 5,364 shares to hold 46,366 shares valued at $17.14 million. This reduction occurred despite Stryker's strong financial performance, which saw EPS of $4.47 and revenue of $7.17 billion, exceeding analyst expectations. Additionally, insiders, including Director Ronda E. Stryker, sold a significant number of shares, indicating some level of insider selling activity.
Hospital Robotics (Logistics and Pharmacy) Market to Reach USD 14.77 Billion by 2033 at 13.3% CAGR | North America Holds 40% Share | Key Players: Omnicell, Inc., Aethon Inc., Swisslog Healthcare
The hospital robotics market for logistics and pharmacy is projected to grow from USD 4.8 billion in 2024 to USD 14.77 billion by 2033, exhibiting a CAGR of 13.3%. This growth is primarily driven by increasing hospital workloads, the complexity of medication management, and shortages of skilled healthcare personnel, particularly in North America which holds a 40% market share. Key players in this market include Omnicell, Inc., Aethon Inc., and Swisslog Healthcare, who are expanding the deployment of autonomous mobile robots and advanced pharmacy dispensing systems to enhance efficiency and patient safety.
A Look At Abbott Laboratories (ABT) Valuation As Libre 3 Lawsuit Raises Product Safety Concerns
Abbott Laboratories (ABT) is facing a wrongful death lawsuit concerning alleged defects in its FreeStyle Libre 3 glucose monitors, impacting investor perception of product safety risks. Despite recent share price declines related to these legal issues and other transient headwinds, a popular narrative suggests the stock is 15.5% undervalued with a fair value of $133.39, projecting future growth from new product launches and regulatory expansions. However, an alternative Discounted Cash Flow (DCF) analysis indicates the current share price of $112.68 is above its estimated value of $95.81, suggesting less room for error if growth or margins don't meet expectations.
Vanguard Group Inc. Acquires 272,828 Shares of Stryker Corporation $SYK
Vanguard Group Inc. increased its stake in Stryker Corporation by 0.8% in the third quarter, acquiring an additional 272,828 shares, bringing its total holding to 33,773,399 shares valued at approximately $12.49 billion. This makes Vanguard one of the largest institutional holders of Stryker stock, owning about 8.83% of the company. The article also details recent insider selling, analyst ratings, and Stryker's strong quarterly earnings beat and dividend announcement.
Public Sector Pension Investment Board Trims Stake in Stryker Corporation $SYK
The Public Sector Pension Investment Board significantly reduced its stake in Stryker Corporation (NYSE:SYK) by 86.9% in the third quarter, selling 199,930 shares and retaining 30,210 shares valued at approximately $11.17 million. Despite this, Stryker reported strong quarterly earnings, beating EPS estimates and seeing an 11.4% year-over-year revenue increase, with a consensus analyst rating of "Moderate Buy" and a $426.94 price target. Insiders, including Director Ronda E. Stryker and CFO Preston Wendell Wells, also sold shares, though institutional investors still own 77.09% of the company's stock.
Assessing Stryker (SYK) Valuation After New Trauma Launch And Better Than Expected Earnings
Stryker (SYK) has launched a new trauma product and reported better-than-expected earnings, leading analysts to assess its valuation. Despite the recent positive news and a strong balance sheet, the stock is considered "Fair Priced" with a slight overvaluation according to one narrative, resting at an estimated intrinsic value slightly above its current market price and below analyst targets. The article suggests Stryker must deliver strong free cash flow growth in the next three years to justify its current valuation.
Shell Asset Management Co. Has $2.68 Million Stake in Stryker Corporation $SYK
Shell Asset Management Co. has reduced its stake in Stryker Corporation by 56.1% in Q3, now owning 7,253 shares valued at approximately $2.68 million. This comes as Director Ronda E. Stryker sold a significant number of shares, reducing her ownership. Despite the institutional selling, Stryker beat quarterly earnings expectations and announced a quarterly dividend, maintaining a "Moderate Buy" consensus rating from analysts.
Aberdeen Group plc Reduces Holdings in Stryker Corporation $SYK
Aberdeen Group plc reduced its stake in Stryker Corporation (NYSE:SYK) by 6.1% in the third quarter, selling 19,998 shares. Following this, the firm now owns 308,666 shares of the medical technology company, valued at $114,169,000. Institutional investors and hedge funds own 77.09% of Stryker's stock, which recently announced a quarterly dividend of $0.88 per share.
ABN Amro Investment Solutions Has $52.35 Million Stock Holdings in Stryker Corporation $SYK
ABN Amro Investment Solutions recently reduced its stake in Stryker Corporation (NYSE:SYK) by 16.6% in the third quarter, now holding 141,616 shares valued at $52.35 million. Despite the reduction, Stryker remains a significant position in ABN Amro's portfolio. Other institutional investors like Princeton Global Asset Management and Kovack Advisors Inc. increased their holdings, while company insiders, including Director Ronda E. Stryker and CFO Preston Wendell Wells, sold portions of their shares.
Is It Time To Reassess Boston Scientific (BSX) After Its Recent Share Price Slide
Boston Scientific (BSX) has seen a significant share price decline, making investors question its long-term potential. A Discounted Cash Flow (DCF) analysis by Simply Wall St suggests the stock is undervalued by 27.3%, arriving at an intrinsic value of US$102.73 per share compared to the current US$74.73. However, its P/E ratio aligns closely with market expectations, categorized as "about right" when compared to a proprietary "Fair Ratio."
Stryker’s New Humerus System Deepens Trauma Platform And Surgeon Ties
Stryker has launched the T2 Alpha Humerus Nailing System, a new trauma solution utilizing its SOMA technology to enhance efficiency and consistency in humerus fracture procedures. This strategic product release aims to standardize complex upper extremity trauma care for hospitals and surgeons, reinforcing Stryker's established presence in orthopedics. For investors, this move is seen as a way to deepen hospital relationships and surgeon loyalty, rather than a driver of short-term stock fluctuations.
Stryker launches T2 Alpha humerus nailing system for fracture care
Stryker has introduced its T2 Alpha Humerus Nailing System, a new solution for treating a wide range of humeral fractures. This system is designed to provide improved intraoperative flexibility and stability, addressing some of the challenges in complex fracture care. The launch aims to reduce complications and enhance patient outcomes in upper extremity trauma.
Stryker announces limited release of handheld robotic system for knee surgery
Stryker has announced the limited market release of Mako RPS (Robotic Power System) for Total Knee, an intuitive handheld robotic system. This new system combines Stryker's robotics and power tool expertise, expanding the Mako platform beyond its existing Mako SmartRobotics. Mako RPS offers surgeons a solution that integrates robotic technology with the familiarity of a manual power tool, featuring intraoperative planning and active adjustment technology for precise guidance during knee surgery.
Stryker launches T2 Alpha Humerus Nailing System, supporting surgical workflow and care for complex fractures
Stryker has launched its T2 Alpha Humerus Nailing System, designed to streamline humeral fracture fixation and provide consistent, high-quality care for complex humerus fractures, including non-unions and malunions. The system utilizes Stryker’s SOMA technology for an anatomical fit and includes features like active intraoperative compression and multiplanar screw fixation. This new offering aims to enhance surgical flexibility, drive efficiency in the operating room, and expand treatment options for surgeons.
Medtronic wins FDA nod for surgical robot for spine procedures
Medtronic (NYSE: MDT) has received FDA clearance for its Stealth AXiS robotic system for spine surgery in the U.S. This system integrates planning, navigation, and robotics into a single platform and is designed for use in both hospitals and ambulatory surgery centers. A key innovation is the LiveAlign sentimental tracking feature, which allows surgeons to visualize real-time anatomic motion and patient alignment without repeated imaging, aiding in more consistent execution of surgical plans.
Illinois Municipal Retirement Fund Grows Position in Stryker Corporation $SYK
The Illinois Municipal Retirement Fund significantly increased its stake in Stryker Corporation by 42.8% in Q3, now holding 36,554 shares valued at $13.51 million. This comes as Stryker reported strong quarterly earnings, beating estimates with $4.47 EPS and $7.17 billion in revenue, and declared a quarterly dividend of $0.88. However, a director recently sold a substantial number of shares, reducing her position by over 9%.
PEN Stock Price, Forecast & Analysis | PENUMBRA INC (NYSE:PEN)
This article provides a detailed analysis of Penumbra Inc. (NYSE: PEN) stock, covering its price performance, technical and fundamental ratings, financial highlights, and analyst forecasts. The company, which specializes in medical devices for thrombectomy, has a current stock price of $339.3 USD and analysts forecast a 7.34% price increase in the next year. It also details the company's profile, including its products, market, and key financial statistics.
Assessing Becton Dickinson (BDX) Valuation After Recent Share Price Weakness
Becton Dickinson (BDX) has experienced a nearly 9% year-to-date decline in share price, now trading at $177.81 with an intrinsic value gap of about 21% and a 10% discount to analyst targets. Despite recent weakness, the company is seen as undervalued with a fair value estimate around $205, supported by the upcoming separation of its Biosciences and Diagnostic Solutions business, its focus on medical technology, and anticipated share buybacks. However, risks include tariff pressures and execution challenges related to the business separation.
Alps Advisors Inc. Decreases Stock Position in Stryker Corporation $SYK
Alps Advisors Inc. significantly reduced its stake in Stryker Corporation (NYSE:SYK) by 54.6% in the third quarter, selling 3,622 shares and holding 3,012 shares valued at $1.11 million. This comes as company insiders have also been net sellers, offloading 252,118 shares for $91.5 million in the last 90 days. Despite these sales, Stryker delivered a strong quarterly performance, beating EPS estimates, increasing revenue by 11.4% year-over-year, and maintaining a "Moderate Buy" consensus rating with an average target price of $426.94.
Caprock Group LLC Purchases Shares of 10,070 Stryker Corporation $SYK
Caprock Group LLC has acquired 10,070 shares of Stryker Corporation (NYSE:SYK), a medical technology company, valued at approximately $3.94 million in the third quarter. Despite this purchase, insiders have collectively sold 252,118 shares worth roughly $91.5 million over the past three months, including a significant sale by Director Ronda E. Stryker. Stryker reported strong quarterly earnings, beating analyst estimates with $4.47 EPS and 11.4% year-over-year revenue growth, and maintains a "Moderate Buy" consensus rating from analysts with a target price of $426.94.
Stryker Launches T2 Alpha Humerus Nailing System for Fracture Care
Stryker has launched the T2 Alpha Humerus Nailing System, expanding its T2 Alpha portfolio for humeral fracture fixation. This new system aims to simplify surgical procedures and improve patient care with its anatomically informed design and advanced fixation capabilities. The launch is expected to strengthen Stryker's trauma and orthopedics portfolio and contribute to revenue growth in the global orthopedic trauma market, which is projected to reach $16.55 billion in 2026.
Does Stryker’s New Ortho-Robotics Launch and Results Reset the Bull Case For SYK?
Stryker recently launched the T2 Alpha Humerus Nailing System and began a limited market release of its Mako RPS handheld robotic system for total knee procedures. These new product offerings, along with reported full-year 2025 sales of US$25.12 billion and net income of US$3.25 billion, aim to strengthen Stryker's orthopedic and robotics ecosystem. The Mako RPS handheld system is particularly noted for potentially broadening the use cases for robotic-assisted knee procedures and reinforcing the company's investment narrative in orthopedic robotics growth, despite ongoing risks like supply chain disruptions.
Stryker says DOJ, SEC have closed bribery probes
Stryker announced that the U.S. Justice Dept. and Securities and Exchange Commission have concluded their probes into potential anti-bribery law violations, which began in May 2023. The investigations focused on business activities in an undisclosed foreign country to determine if Stryker violated the Foreign Corrupt Practices Act (FCPA). Although the company has had previous FCPA violations, Stryker stated that ongoing inquiries by certain foreign authorities are not expected to materially affect its financial statements.
ING Groep NV Makes New $18.55 Million Investment in Stryker Corporation $SYK
ING Groep NV has acquired a new stake of 50,181 shares, valued at $18.55 million, in Stryker Corporation during the third quarter. This investment is part of broader institutional trading activity, with other hedge funds also adjusting their positions in SYK. The article also details recent insider selling by a director and CFO, alongside updated analyst ratings and the company's financial performance indicators.
Avanos Medical, Inc. (NYSE:AVNS) Held Back By Insufficient Growth Even After Shares Climb 26%
Avanos Medical (NYSE:AVNS) shares recently surged 26%, yet the company's price-to-sales (P/S) ratio of 1x remains low compared to the Medical Equipment industry average. This low P/S ratio is attributed to the company's sluggish revenue growth, which has lagged behind competitors, with analyst forecasts predicting only 0.9% growth next year versus 52% for the industry. Despite the recent stock increase, the insufficient growth outlook continues to deter investors from valuing the stock higher.
Insider Selling: Mercury Systems (NASDAQ:MRCY) Director Sells 400,000 Shares of Stock
Jana Partners Management, LP, a director at Mercury Systems (NASDAQ:MRCY), sold 400,000 shares of the company's stock for $32.4 million at an average price of $81.00 on February 9th, reducing their stake by 8.05%. This comes as Mercury Systems reported Q4 EPS of $0.16 and revenue of $232.87 million, both above estimates, though analysts project a negative EPS for the current year. The stock traded down to $80.33 mid-day, and analyst coverage for MRCY is mixed with a "Hold" consensus rating and a target price of $86.89.
Is Stryker Corp Gaining or Losing Market Support?
Stryker Corp's short interest has decreased by 12.4% since its last report, now standing at 1.13% of its float, indicating a potentially more bullish sentiment from investors. The company's short interest is also significantly lower than its peer group average of 5.98%. This data suggests that while a decrease in short interest doesn't guarantee a stock price rise, fewer shares are being shorted compared to previous periods and its competitors.
Enovis (ENOV) Valuation Check As Positive Analyst Views Follow A Difficult Year
Enovis (ENOV) is attracting renewed attention due to its presentation at the Annual MedTech conference, despite a challenging prior year with significant share price decline. Analysts view the stock as undervalued, with a fair value of $45.09 against a current price of $22.80, based on expected operational improvements and earnings growth. However, this positive outlook depends on successful integration of acquisitions and timely tech launches, with potential risks if delays occur.
STIM Stock Price, Forecast & Analysis | NEURONETICS INC (NASDAQ:STIM)
This article provides an analysis of NEURONETICS INC (NASDAQ:STIM), including its stock price, forecast, and key financial statistics. It highlights that STIM's stock price is currently $1.42 USD, having decreased significantly over the past year, and notes the company's low technical and fundamental ratings from ChartMill. Despite this, analysts have an average price target that implies a substantial increase in the next year, coupled with expectations for EPS and revenue growth.
Stryker says US SEC drops foreign bribery probe
The US Securities and Exchange Commission has concluded its investigation into Stryker Corp. regarding alleged violations of the Foreign Corrupt Practices Act. Stryker announced in its annual earnings report that the SEC has closed the inquiry, indicating no further action will be taken.
